Short answer: in the U.S., lurbinectedin is very expensive, and its total cost for a course of treatment is generally in the six-figure range. Many other “new” cancer therapies (whether newer chemotherapies, targeted therapies, or immunotherapies) also carry high price tags, often in the tens of thousands per month or per cycle, with some regimens exceeding $100,000 per course depending on duration and dosing.
A bit more detail to put it in context:
- Lurbinectedin dosing for metastatic platinum‑resistant small cell lung cancer is given in cycles (e.g., every 21 days for up to a few cycles). Because the drug is new and specialized, the list price per course tends to be high, and the total cost can reach six figures depending on how many cycles are used.
- By contrast, other newly approved cancer therapies often cost in similar ranges per cycle or per month:
- Some immune checkpoint inhibitors and combination regimens: roughly $10,000–$20,000 per cycle or per infusion, with monthly costs varying by regimen.
- Some targeted therapies (e.g., certain EGFR or ALK inhibitors) can run around $15,000 per month (or more, depending on dosing and duration).
- Other costly agents (e.g., certain antibody–drug conjugates) can also be in the $10,000–$20,000 per cycle range or higher.
- All of these are list prices; actual out-of-pocket costs for patients depend heavily on insurance coverage, negotiated discounts, manufacturer patient-assistance programs, and country/region.
If you want a precise comparison, tell me:
- the country or region (U.S. vs Europe vs another country),
- which specific drugs you want to compare with lurbinectedin (e.g., osimertinib, pembrolizumab, belantamab mafodotin, etc.),
- and whether you want list prices or typical net prices/patient out-of-pocket costs.
I can then pull the current pricing landscape and give you a more exact, side-by-side picture.